Reading a Peptide Research Study — A Glossary of Terms

Peptide research papers are written for specialist audiences: biochemists, pharmacologists and clinical trialists. For anyone else trying to evaluate whether a published study actually supports a claim made about a compound, the methodological language can be opaque to the point of misleading. A study conducted in a cell-line incubator is categorically different from one conducted in a human hospital ward, yet both can be cited as "studies have shown" in the same breath. This article defines the core terms.

Experimental system terminology

In vitro

In vitro (Latin: "in glass") describes experiments conducted in a controlled, artificial environment outside a living organism — typically in cell culture wells, test tubes, or microfluidic chips. Peptide concentrations in these systems can be set at any arbitrary value, receptor expression is governed by the cell line chosen, and there is no pharmacokinetic degradation, blood-brain barrier, renal clearance or hepatic metabolism operating.

In vitro results establish mechanistic plausibility — they show that a peptide can bind a receptor, activate a pathway, or modulate a cellular behaviour under optimised conditions. They do not establish that the peptide will reach the relevant tissue at sufficient concentrations in a living organism, nor that the effect size observed at nano-molar concentrations in culture will recapitulate at the doses achievable in vivo.

Ex vivo

Ex vivo describes tissue or organs removed from a living organism and studied outside the body while they are still viable. A perfused rat heart, a section of bowel mounted in an organ bath, or a skin biopsy maintained in culture medium are ex vivo preparations. These systems preserve tissue architecture and local signalling more faithfully than cell lines, but the removed tissue is still disconnected from systemic circulation, hormonal regulation, and immune surveillance. Ex vivo results sit between in vitro and in vivo in their translational weight.

In vivo

In vivo (Latin: "within the living") describes experiments conducted in whole living organisms — typically rodents (mice, rats), but also rabbits, pigs, or non-human primates in later-stage preclinical work. In vivo studies allow pharmacokinetic assessment — how the compound is absorbed, distributed, metabolised, and eliminated — and pharmacodynamic assessment at the system level. Animal-model results are more translatable than cell culture, but species differences in receptor expression, metabolism, and injury biology introduce significant uncertainty. This problem is discussed in depth in the companion article Why Animal-Model Peptide Studies Don't Translate to Human Outcomes.

Animal model terminology

Rodent models and strain specificity

Most published peptide research uses Sprague-Dawley rats or C57BL/6 mice. Strain matters: inbred strains can have fixed receptor polymorphisms, altered hepatic enzyme profiles, or constitutively elevated inflammatory tone that is not representative of the heterogeneous human population. A finding in C57BL/6 mice may not replicate in BALB/c mice, let alone in humans.

Sham surgery controls

A well-designed animal study includes a sham group — animals subjected to the same surgical procedure as the experimental group, but without the induced injury. Sham controls distinguish between the effect of the compound and the effect of the surgical trauma alone. Studies without sham controls should be interpreted with caution.

n values and statistical power

The number of animals per group (n) determines the statistical power of the study. Many peptide papers report n = 6–10 per group. At these sample sizes, only large effect sizes reach statistical significance at p < 0.05; small to moderate effects are systematically missed. This means a negative result in a small-n study does not establish that the compound is ineffective [PMID:27578035].

Clinical trial phase terminology

Phase I

Phase I trials are first-in-human studies focused on safety, tolerability and pharmacokinetics rather than efficacy. They typically enrol 20–80 healthy volunteers. A compound that has completed Phase I has a provisional human safety profile, but no proof of clinical efficacy. Tesamorelin, now FDA-approved for HIV-associated lipodystrophy, passed through Phase I to establish its GH-stimulation pharmacokinetics in healthy subjects [PMID:17638583].

Phase II

Phase II trials are proof-of-concept efficacy studies, typically 100–300 patients with the target condition. They establish whether the compound has a detectable therapeutic signal and inform dose-selection for Phase III. Retatrutide's published Phase II data — approximately 24% mean body weight reduction at 48 weeks in the 12 mg arm — represents the current evidence basis for that compound [PMID:37389770].

Phase III

Phase III trials are pivotal, randomised, double-blind, placebo-controlled studies with sample sizes typically in the thousands, designed to confirm efficacy and characterise the full adverse-event profile. Regulatory approval requires completion of at least one pivotal Phase III trial. Most research peptides discussed on PeptideStacks.co.uk have not entered Phase III. BPC-157, despite 30+ years of rodent literature, has no completed Phase III trial data.

Phase IV (post-marketing surveillance)

Phase IV studies are conducted after regulatory approval to monitor long-term safety in the real-world prescribing population. Tirzepatide, which holds FDA approval (Mounjaro; Zepbound) and UK MHRA authorisation, now has a growing Phase IV evidence base.

Regulatory and classification terminology

GRAS

GRAS — Generally Recognised As Safe — is a US FDA designation for food and food-additive substances. Some amino acid sequences are GRAS; this does not confer any therapeutic safety claim and does not imply that a peptide compound derived from those sequences is safe for pharmacological use at arbitrary doses.

POM

Prescription-Only Medicine (UK) or Rx (US). Tirzepatide and semaglutide are POM in the UK — they cannot be legally sold without a prescription. Research-grade equivalents of POM molecules supplied to laboratories occupy an ambiguous position under UK medicines law. See the UK peptide regulation 2026 article for the full MHRA position.

IND

An Investigational New Drug application (IND) is filed with the US FDA before a sponsor can begin clinical trials in humans. Approval of an IND means the FDA has reviewed preclinical safety and manufacturing data and found them sufficient to permit human experimentation. IND status is not therapeutic approval — it is a licence to study. Many compounds circulating in research-peptide communities have never had an IND filed.

NDA / BLA / MA

New Drug Application (NDA, for small molecules), Biologics Licence Application (BLA, for biologics including many peptides), and Marketing Authorisation (MA, the European and UK equivalent) represent full regulatory approval for commercial sale as medicinal products. Achieving NDA/BLA/MA typically requires 10–15 years of development and hundreds of millions in investment.

Red flags in published literature

"Studies have shown"

This phrase without citation is the clearest marker that the text is not engaging with the primary literature. A statement followed by a PubMed citation — [PMID:XXXXXXXX] — allows independent verification. A statement followed by "studies have shown" does not.

Dose extrapolation without allometric scaling

When an animal-model paper cites a dose in mg/kg, and a commercial source simply multiplies by the buyer's body weight to derive a human dose, this omits allometric scaling — the recognised formula for converting doses between species based on metabolic rate and body surface area. A 10 mg/kg dose in rats does not translate to a 700 mg dose in a 70 kg human; the metabolic scaling formula reduces this substantially. The translation problem is detailed in Why Animal-Model Peptide Studies Don't Translate to Human Outcomes.

Single-group, no-control designs

A study measuring a biomarker before and after peptide administration in a single group of animals, without a saline-control group, cannot distinguish the compound's effect from regression to the mean, spontaneous recovery, or placebo physiology. These designs are published and cited, but their evidential weight is low [PMID:23159321].

How to find primary papers on PubMed

PubMed (pubmed.ncbi.nlm.nih.gov) is the primary index for biomedical literature. Effective search strategies for peptide research include:

• Searching by compound name plus the injury model: "BPC-157 tendon" returns the tendon-repair literature specifically
• Filtering by species: "BPC-157 tendon[Title] AND rat[Title/Abstract]" isolates rodent data
• Using the "Clinical Trial" publication-type filter to exclude preclinical papers from a clinical-evidence assessment
• Checking the citing papers for any key study — PubMed's "Cited by" function shows subsequent work, including failed replications

For per-compound research summaries and individual peptide monographs, PeptideAuthority.co.uk maintains curated literature pages for each compound with direct PubMed links organised by tissue system and study type.